Newron Pharmaceuticals SpA earnings date
Newron Pharmaceuticals SpA (NP5) Q4 2025 Earnings Report
DE:NP5 Q4 2025 EPS Results
- Actual EPS
- -EUR 0.66
- Consensus EPS
- -EUR 0.08
- Beat/Miss
- Missed by -EUR 0.58
- One Year Ago EPS
- EUR 1.20
DE:NP5 Q4 2025 Revenue Results
- Actual Revenue
- EUR 7.27M
- Expected Revenue
- EUR 5.30M
- Beat/Miss
- Beat by +EUR 1.97M
- YoY Revenue Growth
- -85.11%
Earnings Announcement Details
- Quarter
- Q4 2025
- Date
- 03/24/2026
- Time
- Before Open
- Conference Call
- Tuesday, March 24, 2026
Newron Pharmaceuticals SpA's next earnings date is estimated for March 16, 2027, based on past reporting schedules.
Q4 2025 Earnings Call Audio
Q4 2025 Earnings Slide Deck
Q4 2025 Earnings Call Summary
The call presented multiple strong positive developments: validation from a top-tier partner (Eisai) and EUR 48m collected, a large global pivotal program across >1,300 patients with significant Phase III/Phase II efficacy signals (8A: PANSS p=0.006; CGI-S p=0.037), an improved IP position (European crystalline patent and potential U.S. grant to extend exclusivity to 2044), robust safety/tolerability and clear commercial expansion potential. Management has secured non-dilutive runway and delayed debt service to mid-2028. Principal risks flagged were operational recruitment challenges, parts of funding conditional on positive results (EUR 12m), pending U.S. patent timing, and the fact that a NASDAQ uplisting is not currently achievable without further progress. On balance the highlights (clinical validation, funding, IP progress, safety, analyst coverage) substantially outweigh the lowlights, though the company remains dependent on upcoming pivotal readouts and execution.
Guidance from the call was that Newron expects 12‑week pivotal readouts within 2026 and aims to complete enrollment in ENIGMA‑TRS‑1 (a 600‑patient, 52‑week TRS study with a 12‑week primary endpoint) by end‑August 2026 with primary results by year‑end and a likely NDA filing in Q1–Q2 2027; ENIGMA‑TRS‑2 (a shorter 12‑week pivotal) may report topline in Q4‑26/early‑Jan and announcements will be separate. Management said the company is running three pivotal studies (>1,300 patients worldwide), has the cash to reach the 12‑week readouts (EUR 48m received from the Eisai deal plus access to up to EUR 38m new financing: EUR 15m already in the bank, EUR 11m expected before year‑end, and EUR 12m conditional on positive pivotal results), and that a positive readout would likely unlock the conditional EUR 12m and extend runway into late‑2027 (an extra ~6–9 months per management). The European Investment Bank loan repayments were deferred to not before June 2028, shareholders will vote on April 23, 2026 on a 15% capital increase (and 5% for option plans) to support additional indications/uplisting, and Newron noted ~20.8m shares outstanding, ~1.6m warrants, daily turnover of ~0.7–1% of the stock and a pending crystalline‑form composition‑of‑matter patent that could extend exclusivity to 2044 (current US COM to 2035; process patents to 2042).
- Strategic Partnership and Initial Funding SecuredDecember 2024 licensing deal with EA (Eisai Group) validated evenamide and generated EUR 48 million collected to advance Phase III. New funding agreement provides access up to EUR 38 million (EUR 15m already in bank, EUR 11m expected before year-end with no milestones attached, and EUR 12m conditional on positive pivotal results). European Investment Bank loan repayments delayed to no earlier than June 2028, improving near-term liquidity runway.
- Pivotal Clinical Program Now Large and GlobalRunning three pivotal studies across >1,300 patients worldwide: ENIGMA-TRS1 (600-patient, 52-week double-blind placebo-controlled TRS study with 12-week primary readout), ENIGMA-TRS2 (U.S.-initiated pivotal study), plus partner Eisai's Phase III program. Management expects 12-week readouts within the year and enrollment completion milestones (TRS1 enrollment expected to complete by end of August).
- Positive Clinical Efficacy Signals and Durable EffectsPhase III 8A (4-week, n=291) produced statistically significant efficacy: PANSS total p=0.006 and CGI-S p=0.037. Earlier 1-year add-on data in treatment-resistant schizophrenia showed large improvements (management described 'doubling/tripling' responder rates over 1 year and ~50% of patients no longer meeting treatment-resistant criteria, with reports of 6-month remission). Simulations project 12–14 point PANSS improvement at week 12 and 14–19 points by week 26.
- Favorable Safety and Low AttritionEvenamide exhibits a benign safety profile in trials: the most common AE was nasopharyngitis with incidence similar to placebo, and trials reported no clinically relevant extrapyramidal symptoms, weight gain, metabolic effects, sexual dysfunction, ECG, liver or kidney signal. Reported attrition rates <5%.
- Strengthened IP Position with Potential Extended ExclusivityEuropean patent on crystalline forms of evenamide granted (filed earlier) and expected to be approved in other key territories; if granted in the U.S., this could extend market exclusivity to 2044 (~17 years post expected approval at end-2027). Existing COM in U.S. runs to 2035 and process patents to 2042; company actively pursuing accelerated U.S. prosecution.
- Improved Market Perception and Institutional InterestThree new U.S. analyst coverage additions (Wainwright, ROTH Capital, Lucid) plus additional European coverage; management cites liquidity having 'doubled or tripled' and daily trading between ~0.7%–1.0% of shares outstanding. Shares outstanding ~20.8 million; outstanding warrants/call options up to ~1.6 million.
- Clear Commercial Opportunity and Indication Expansion PotentialEvenamide is positioned as the first glutamate-modulating add-on for schizophrenia with potential to address negative symptoms and cognition; management and CMO highlighted additional attractive indications (bipolar disorder, treatment-resistant depression with psychotic features, behavioral symptoms in dementia). Comparators/precedents (Karuna, Intra-Cellular) were cited to illustrate potential commercial upside.
- Tax and Non-Operational Financial BenefitsR&D tax credit benefit of EUR 1.9 million booked in 2025; accumulated R&D tax benefits since 2025 total ~EUR 25 million, of which ~EUR 22 million have been used (~88% utilized).
DE:NP5 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 16, 2027 | 2026 (Q4) | -0.77- | -0.66 | ― | ― |
| Sep 22, 2026 | 2026 (Q2) | -0.19-0.80 | 0 | ― | |
| Mar 24, 2026 | 2025 (Q4) | -0.08-0.66 | 1.2 | -154.95% (-1.86) | |
| Sep 16, 2025 | 2025 (Q2) | -0.410.00 | -0.51 | 100.00% (+0.51) | |
| Apr 01, 2025 | 2024 (Q4) | ―1.29 | -0.54 | 341.16% (+1.83) | |
| Sep 19, 2024 | 2024 (Q2) | ―-0.51 | -0.39 | -30.77% (-0.12) | |
| Mar 19, 2024 | 2023 (Q4) | ―-0.54 | -0.52 | -2.47% (-0.01) | |
| Aug 04, 2023 | 2023 (Q2) | ―-0.39 | -0.48 | 18.75% (+0.09) | |
| Mar 14, 2023 | 2022 (Q4) | ―-0.52 | -0.38 | -39.26% (-0.15) | |
| Sep 15, 2022 | 2022 (Q2) | ―-0.48 | -0.51 | 5.88% (+0.03) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


